BioCentury | Jun 25, 2019
Finance

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

With $67 million in series A funding, newly launched Frontier Medicines Corp. believes that by using its massive database of protein binding hot spots and applying machine learning to its library of covalent compounds, the...
BC Innovations | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BC Innovations | Mar 22, 2019
Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Innovations | Nov 7, 2018
Translation in Brief

M is for Chemoproteomic Momentum

An October Nature paper from a University of Cambridge team is the second in as many years to highlight the utility of functionalizing methionine, an amino acid that has garnered less attention than others in...
BC Week In Review | May 4, 2018
Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from 51 amyotrophic lateral sclerosis (ALS) patients without non-invasive ventilation in a Phase Ib/IIa trial showing that once-daily 60 mg oral ibudilast (Ketas, AV411, MN-166) plus riluzole non-significantly...
BC Week In Review | May 4, 2018
Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from the Phase IIb SPRINT-MS trial in 255 patients with primary or secondary progressive multiple sclerosis showing that twice-daily oral ibudilast (Ketas, AV411, MN-166) met the secondary endpoint...
BC Week In Review | Apr 6, 2018
Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) said it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis showed that the product...
BC Extra | Apr 2, 2018
Clinical News

Early stop in liver disease trial boosts MediciNova

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) shares rose Monday on news it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis...
BC Week In Review | Mar 30, 2018
Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported on March 29 that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat methamphetamine dependence. The trial enrolled about...
Items per page:
1 - 10 of 195
BioCentury | Jun 25, 2019
Finance

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

With $67 million in series A funding, newly launched Frontier Medicines Corp. believes that by using its massive database of protein binding hot spots and applying machine learning to its library of covalent compounds, the...
BC Innovations | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BC Innovations | Mar 22, 2019
Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Innovations | Nov 7, 2018
Translation in Brief

M is for Chemoproteomic Momentum

An October Nature paper from a University of Cambridge team is the second in as many years to highlight the utility of functionalizing methionine, an amino acid that has garnered less attention than others in...
BC Week In Review | May 4, 2018
Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from 51 amyotrophic lateral sclerosis (ALS) patients without non-invasive ventilation in a Phase Ib/IIa trial showing that once-daily 60 mg oral ibudilast (Ketas, AV411, MN-166) plus riluzole non-significantly...
BC Week In Review | May 4, 2018
Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from the Phase IIb SPRINT-MS trial in 255 patients with primary or secondary progressive multiple sclerosis showing that twice-daily oral ibudilast (Ketas, AV411, MN-166) met the secondary endpoint...
BC Week In Review | Apr 6, 2018
Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) said it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis showed that the product...
BC Extra | Apr 2, 2018
Clinical News

Early stop in liver disease trial boosts MediciNova

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) shares rose Monday on news it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis...
BC Week In Review | Mar 30, 2018
Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported on March 29 that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat methamphetamine dependence. The trial enrolled about...
Items per page:
1 - 10 of 195